GGrantIndex
Sort

53,477 grants matching addiction

Vaping Cessation among youth: Evaluating the feasibility and efficacy of a virtual in-person CBT and an app-based CBT4CBT

$1,003,164
Suchitra Krishnan-Sarin · Yale University · R01 · FY2024 · CA

Novel fluorescent sensors for imaging neuromodulation

$1,002,861
Yang Dan · University Of California Berkeley · U01 · FY2021 · NS

Novel Dopamine D3 Receptor Ligands

$1,002,774
Amy Hauck Newman · National Institute On Drug Abuse · ZIA · FY2013 · DA

Alliance to Disseminate Addiction Prevention and Treatment (ADAPT): A Statewide Learning Health System to Reduce Substance Use among Justice-Involved Youth in Rural Communities.

$1,002,621
Matthew Aalsma · Indiana University Indianapolis · UG1 · FY2020 · DA

The Genetic Basis of Opioid Dependence Vulnerablility in a Rodent Model

$1,002,597
Giordano De Guglielmo · University Of California, San Diego · U01 · FY2025 · DA

Metabolic basis of B cell lineage leukemia relapse

$1,002,111
Markus Mãœschen · Yale University · R35 · FY2021 · CA

STRESS AND PTSD MECHANISMS AS TARGETS FOR PHARMACOTHERAPY OF ALCOHOL ABUSE, ADDICTION AND RELAPSE

$1,002,099
Seattle Institute For Biomedical And Clinical Research · · FY2013 · Department of Defense

A staged, comprehensive investigation for developing insular deep brain stimulation to treat refractory chronic pain

$1,002,003
William Jeffrey Elias · University Of Virginia · UH3 · FY2023 · NS

Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS Therapy in Alcohol Addiction Treatment

$1,001,961
Roger Brooks Bagwell · Actuated Medical, Inc. · R44 · FY2024 · AA

Development of KLS-13019 for Neuropathic Pain

$1,001,774
Douglas Eric Brenneman · Kannalife Sciences, Inc. · R42 · FY2023 · NS

Center for the Development of Novel Medications for Cocaine Dependence

$1,001,222
Kyle Matthew Kampman · University Of Pennsylvania · U54 · FY2017 · DA

17/24 Healthy Brain and Child Development National Consortium

$1,001,022
Sylia Wilson · University Of Minnesota · U01 · FY2021 · DA

Administrative Core

$1,000,548
Frederick Gerard Moeller · University Of Texas Hlth Sci Ctr Houston · P50 · FY2012 · DA

Hallucinogens and 5-HT Receptors: Mechanisms and Effects

$1,000,180
Harel Weinstein · Weill Medical Coll Of Cornell Univ · P01 · FY2009 · DA

Development of anti-sense oligonucleotides as a therapeutic for cancer pain through selective block of sodium channel pain targets

$1,000,001
Hongkang Zhang · Quiver Bioscience Inc. · R44 · FY2021 · CA

IGF::OT::IGF RELAPSE PREVENTION MOTION AND VOICE VIDEO GAME; POP: 9/2/2014-9/1/2016; N44DA-14-4419 SBIR Phase II (Topic 150) Modification to Remove IT Risk Assessment requirements.

$1,000,000
Daniel Greenberg · Media Rez, Llc · N44 · FY2014 · DA

NIDA Clinical Trials Network: New York Node

$1,000,000
John P Rotrosen · New York University School Of Medicine · UG1 · FY2021 · DA

Early Stage Development of a Selective Kappa Opioid Receptor (KOR) Antagonist to Treat Alcohol Use Disorder

$1,000,000
Ronald N Marcus · Cerecor. Inc. · U44 · FY2016 · AA

NIDA CENTGER FOR GENETIC STUDIES

$1,000,000
Rutgers The St Univ Of Nj New Brunswick · N01 · FY2000 · DA

SCC-CIVIC-FA Track B: Participatory Action Research to Enhance Equity and Prevent Moral Injury in Community Paramedicine

$1,000,000
Miranda Worthen · San Jose State University Foundation · · FY2023 · CSE

Mid Southern Primary Care Networks Node

$999,998
Li-Tzy T Wu · Duke University · UG1 · FY2019 · DA

BETTER TOGETHER: INTEGRATING MOUD IN AFRICAN AMERICAN COMMUNITY SETTINGS. SEPTEMBER 15, 2023 TO JANUARY 31, 2026. N01DA-22-2253. TASK ORDER 75N95023F00004 (TO8).

$999,995
Jennifer McCormack · The Emmes Company, Llc · N01 · FY2023 · DA

Micronized salsalate in a parenteral formulation is a safe and effective analgesic for acute postoperative pain management

$999,994
Joel Steven Ross · Rh Nanopharmacueticals L.L.C. · R44 · FY2021 · NS

Development of Nociceptin Receptor Agonists for Alcohol Use Disorders, Period of Performance 09/15/15 - 09/14/17; CPFF

$999,993
Nurulain Zaveri · Astraea Therapeutics, Llc · N44 · FY2015 · HD

Novel biologic to treat chemotherapy-induced neuropathic pain

$999,967
Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2022 · CA